Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen will report its second quarter financial results on August 4, 2022, after U.S. market close. A conference call with senior management, including CEO Robert A. Bradway, is scheduled for 2:00 p.m. PT. The call will be accessible via live audio broadcast online and will be archived for at least 90 days. Amgen, a leader in biotechnology since 1980, is focused on serious illnesses and is part of the Dow Jones Industrial Average and Nasdaq-100. The company is recognized for its significant contributions to health and was named one of the 25 World's Best Workplaces™.
The Amgen Foundation has announced a significant increase in its investment in LabXchange, an online science education platform, by more than doubling its initial funding to a total of $30 million. This initiative, in partnership with Harvard's Vice Provost of Advances in Learning, aims to enhance access to quality science education for students and educators globally. LabXchange, which has registered 20 million users across 230 countries, plans to expand its offerings, including content in multiple languages and addressing inequities in STEM education.
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43rd Annual Healthcare Conference on June 15, 2022, at 1:40 p.m. ET. Key executives, David M. Reese and Peter H. Griffith, will discuss the company's developments. The event will be accessible via a live webcast for media, investors, and the public, and will be archived for 90 days post-event.
Amgen is a leading biotechnology company focused on serious illnesses, with a robust pipeline and a commitment to improving health outcomes.
Amgen announced FDA approval for RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, for treating adults with moderate to severe rheumatoid arthritis (RA) who have not responded to TNF antagonist therapies. RIABNI is already approved for several conditions, including Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. The clinical study showed RIABNI's efficacy and safety are equivalent to Rituxan. This move enhances Amgen's portfolio of biosimilars, reinforcing its commitment to affordable treatment options.
Amgen and Takeda have presented data from the Phase 3 PARADIGM trial at ASCO 2022, demonstrating the efficacy of Vectibix (panitumumab) over bevacizumab in treating unresectable wild-type RAS metastatic colorectal cancer. The trial involved 823 chemotherapy-naive patients and revealed significant improvements in overall survival (OS) with Vectibix, showcasing median OS rates of 37.9 vs. 34.3 months for left-sided tumors. Vectibix's safety profile aligns with previous studies. These results reinforce Vectibix's role as a standard first-line therapy in this patient population.
Amgen will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 9:30 a.m. ET. Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, will lead the presentation, which will be webcast for the media, investors, and the public. The event highlights Amgen's commitment to innovation in biotechnology and advanced human genetics. The webcast will be available for replay for 90 days post-event on Amgen's official website.
Amgen announced positive topline results from its Phase 2 OCEAN(a)-DOSE study, revealing that olpasiran, an investigational treatment, successfully reduced Lipoprotein(a) levels by over 90% in many patients at weeks 36 and 48. The trial involved 281 adult patients with elevated Lp(a) levels and atherosclerotic cardiovascular disease. No new safety issues were reported, and the results are expected to be presented at a future medical congress. These findings could provide new options for patients with limited treatment alternatives for elevated Lp(a).
Amgen will present findings from its oncology portfolio at the ASCO Annual Meeting from June 3-7, 2022. Key updates include the results of the PARADIGM Phase 3 trial comparing Vectibix® with Avastin® for RAS wild-type metastatic colorectal cancer. Additionally, new data on LUMAKRAS® (sotorasib) from the CodeBreaK 100 study highlights resistance mechanisms in KRAS G12C-mutated cancers. This reflects Amgen's commitment to enhancing treatments for challenging cancers. The presentations will cover a range of investigational therapies aimed at improving patient outcomes.
Amgen has launched the 'Double Take' campaign in collaboration with pop icon Lance Bass to raise awareness about psoriatic arthritis. The campaign aims to educate individuals on recognizing early symptoms of the condition, which affects about one million Americans and often goes unnoticed. Bass shares his personal journey of diagnosis and emphasizes the importance of early intervention. The Otezla (apremilast), used for treatment, is highlighted along with its potential side effects, including diarrhea and nausea.
Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference on May 11, 2022, at 12:20 p.m. ET. Key executives, including David M. Reese and Peter H. Griffith, will discuss company developments. The presentation will be available via webcast, accessible to investors and the public, and archived for 90 days. Amgen, a leading biotechnology firm, focuses on innovative treatments for serious illnesses and is recognized for its contributions in healthcare, sustainability, and corporate culture.